Should I buy or sell Evolus stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EOLS shares. View EOLS analyst ratings or view top-rated stocks .

What is Evolus' stock price target for 2024?

3 brokerages have issued twelve-month target prices for Evolus' shares. Their EOLS share price targets range from $16.00 to $27.00. On average, they anticipate the company's share price to reach $20.60 in the next year. This suggests a possible upside of 78.7% from the stock's current price. View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts .

How have EOLS shares performed in 2024?

Evolus' stock was trading at $10.53 on January 1st, 2024. Since then, EOLS shares have increased by 9.5% and is now trading at $11.53. View the best growth stocks for 2024 here .

Are investors shorting Evolus?

Evolus saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 4,650,000 shares, a drop of 6.6% from the March 15th total of 4,980,000 shares. Based on an average daily trading volume, of 657,700 shares, the days-to-cover ratio is presently 7.1 days. Currently, 9.8% of the company's shares are sold short. View Evolus' Short Interest .

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EOLS earnings forecast .

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) released its earnings results on Thursday, March, 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.05. The business had revenue of $61 million for the quarter, compared to the consensus estimate of $61.14 million.

What ETFs hold Evolus' stock?

ETFs with the largest weight of Evolus (NASDAQ:EOLS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2024 earnings guidance on Friday, March, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $261.2 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com . David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI) , ADMA Biologics (ADMA) , Chesapeake Energy (CHKAQ) , Matinas BioPharma (MTNB) , Advanced Micro Devices (AMD) , Dynavax Technologies (DVAX) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , Organigram (OGI) and Bionano Genomics (BNGO) .

Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Who are Evolus' major shareholders?

Evolus' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.24%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi , David N Gill, Karah Herdman Parschauer, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar , Sandra Beaver and Vikram Malik . View institutional ownership trends .

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EOLS

Evolus (EOLS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free EOLS Stock Alerts

$11.53

-0.03 (-0.26%)

(As of 04/19/2024 ET)

Compare

Today's Range: $11.36
▼
$11.61
50-Day Range: $11.56
▼
$14.91
52-Week Range: $7.07
▼
$15.43

Volume: 348,448 shs
Average Volume: 625,641 shs
Market Capitalization: $668.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.60

Get Evolus alerts:

Evolus MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 78.7% Upside
$20.60 Price Target
Short Interest: Healthy
9.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.27
Upright™ Environmental Score
News Sentiment: 0.79
Based on 7 Articles This Week
Insider Trading: Selling Shares
$831,005 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.51) to ($0.05) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.20 out of 5 stars

Medical Sector

137th out of 911 stocks

Pharmaceutical Preparations Industry

46th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Evolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Evolus has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
9.79% of the float of Evolus has been sold short.
Short Interest Ratio / Days to Cover
Evolus has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in Evolus has recently decreased by 6.63%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Evolus does not currently pay a dividend.
Dividend Growth
Evolus does not have a long track record of dividend growth.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Evolus has received a 40.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private dermatologist's appointments", "Private internist's appointments", and "Botulinum toxin" products. See details.
Environmental Sustainability
The Environmental Impact score for Evolus is -1.27.

3.2

News and Social Media Coverage

News Sentiment
Evolus has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Evolus this week, compared to 2 articles on an average week.
Search Interest
Only 6 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
7 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $831,005.00 in company stock.
Percentage Held by Insiders
Only 5.40% of the stock of Evolus is held by insiders.
Percentage Held by Institutions
90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Evolus are expected to grow in the coming year, from ($0.51) to ($0.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Evolus is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evolus is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Evolus Stock (NASDAQ:EOLS)

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EOLS Stock News Headlines

March 30, 2024 | insidertrades.com

Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 6,236 Shares of Stock

March 24, 2024 | insidertrades.com

Evolus, Inc. (NASDAQ:EOLS) CFO Sells $78,954.24 in Stock

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 18, 2024 | investing.com

Evolus reports 6-month efficacy of Jeuveau in glabellar lines study

April 18, 2024 | americanbankingnews.com

Short Interest in Evolus, Inc. (NASDAQ:EOLS) Declines By 6.6%

April 17, 2024 | finance.yahoo.com

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®

April 17, 2024 | businesswire.com

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

April 12, 2024 | businesswire.com

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 11, 2024 | americanbankingnews.com

Evolus (NASDAQ:EOLS) Given Buy Rating at Needham & Company LLC

April 6, 2024 | finance.yahoo.com

Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company

March 26, 2024 | finance.yahoo.com

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 21, 2024 | msn.com

Evolus (NASDAQ:EOLS): An Attractive Aesthetics Stock for Growth Investors

March 20, 2024 | seekingalpha.com

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

March 14, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO) and Evolus (EOLS)

March 12, 2024 | wsj.com

Evolus Inc.

March 12, 2024 | benzinga.com

Latest News for Evolus Stock (NASDAQ:EOLS)

March 11, 2024 | markets.businessinsider.com

Evolus Poised for Growth: Buy Rating Affirmed with $25 Price Target Amid Profitability Forecast and Competitive Market Positioning

March 11, 2024 | markets.businessinsider.com

Evolus Reports Pricing Of $50 Mln Underwritten Offering Of Common Stock

March 11, 2024 | markets.businessinsider.com

Evolus (EOLS) Receives a Buy from Barclays

March 11, 2024 | msn.com

Evolus prices stock offering to raise about $50M

March 11, 2024 | businesswire.com

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

March 10, 2024 | finance.yahoo.com

Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report

March 9, 2024 | finance.yahoo.com

Evolus Full Year 2023 Earnings: In Line With Expectations

March 8, 2024 | msn.com

Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript

March 8, 2024 | businesswire.com

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 8, 2024 | markets.businessinsider.com

Evolus Poised for Growth: Surpassing Q4 Expectations and Accelerating Profitability

See More Headlines

Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EOLS
CUSIP: N/A
CIK: 1570562
Web: www.evolus.com
Phone: (949) 284-4555
Fax: N/A
Employees: 273
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.60
High Stock Price Target: $27.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +79.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-61,690,000.00
Net Margins: -30.52%
Pretax Margin: -30.44%
Return on Equity: N/A
Return on Assets: -32.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.33
Quick Ratio: 2.10

Sales & Book Value

Annual Sales: $202.09 million
Price / Sales: 3.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.36) per share
Price / Book: -31.83

Miscellaneous

Outstanding Shares: 57,940,000
Free Float: 54,815,000
Market Cap: $663.99 million
Optionable: Optionable
Beta: 1.45

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. David Moatazedi (Age 46)
President, CEO & Director
Comp: $1.27M
Ms. Sandra Beaver (Age 46)
Chief Financial Officer
Comp: $372.23k
Dr. Rui Avelar C.CFP (Age 62)
Dip.SportMed, M.D., Chief Medical Officer and Head of Research & Development
Comp: $682.03k
Mr. Nareg Sagherian
Head of Global Investor Relations & Corporate Communications
Mr. Jeffrey J. Plumer
General Counsel
Mr. Kurt Knab
Vice President of Sales
Ms. Tomoko Yamagishi-Dressler
Chief Marketing Officer
Ms. Jessica Novak
Senior Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EOLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Evolus stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings or view top-rated stocks.
What is Evolus' stock price target for 2024?: 3 brokerages have issued twelve-month target prices for Evolus' shares. Their EOLS share price targets range from $16.00 to $27.00. On average, they anticipate the company's share price to reach $20.60 in the next year. This suggests a possible upside of 78.7% from the stock's current price.
View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts.
How have EOLS shares performed in 2024?: Evolus' stock was trading at $10.53 on January 1st, 2024. Since then, EOLS shares have increased by 9.5% and is now trading at $11.53.
View the best growth stocks for 2024 here.
Are investors shorting Evolus?: Evolus saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 4,650,000 shares, a drop of 6.6% from the March 15th total of 4,980,000 shares. Based on an average daily trading volume, of 657,700 shares, the days-to-cover ratio is presently 7.1 days. Currently, 9.8% of the company's shares are sold short.
View Evolus' Short Interest.
When is Evolus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EOLS earnings forecast.
How were Evolus' earnings last quarter?: Evolus, Inc. (NASDAQ:EOLS) released its earnings results on Thursday, March, 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.05. The business had revenue of $61 million for the quarter, compared to the consensus estimate of $61.14 million.
What ETFs hold Evolus' stock?: ETFs with the largest weight of Evolus (NASDAQ:EOLS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has Evolus issued on next quarter's earnings?: Evolus issued an update on its FY 2024 earnings guidance on Friday, March, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $261.2 million.
What is David Moatazedi's approval rating as Evolus' CEO?: 1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Evolus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO).
When did Evolus IPO?: Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.
Who are Evolus' major shareholders?: Evolus' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.24%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Karah Herdman Parschauer, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik.
View institutional ownership trends.
How do I buy shares of Evolus?: Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EOLS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Evolus (EOLS) Stock Price, News & Analysis

Evolus MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Evolus Stock (NASDAQ:EOLS)

EOLS Stock Price History

EOLS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

EOLS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™